Thymalin Research: What 406 Studies Show (2026) | RetatrutideCompare

Thymalin — 406 studies indexed on PubMed. Stimulates T-lymphocyte differentiation and humoral immunity in elderly and immunocompromised patients. Half-life: Variable (mixture). FDA status: Not FDA-approved.

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Thymalin?

There are approximately 406 studies indexed on PubMed that mention Thymalin (Thymus extract polypeptide complex), based on a search last updated 2026-06-18.

Is Thymalin FDA-approved?

FDA status: Not FDA-approved.

How does Thymalin work?

Stimulates T-lymphocyte differentiation and humoral immunity in elderly and immunocompromised patients.

Stimulates T-lymphocyte differentiation and humoral immunity in elderly and immunocompromised patients.

Reference facts

Also known as
Thymus extract polypeptide complex
Category
Khavinson Bioregulators
Mechanism of action
Stimulates T-lymphocyte differentiation and humoral immunity in elderly and immunocompromised patients.
Targets
T-cell differentiation
Indications under research or approved
Approved Russia (immunodeficiency); not US-approved
Regulatory status (reference entry)
Not FDA-approved
Half-life
Variable (mixture)
Sequence notes
Polypeptide mixture extracted from calf thymus, used in Russia and Ukraine as immunomodulator.
First reported
1981

Primary References

Explore research articles about Thymalin

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.